[11] In vivo and in vitro measurement of CYP2C19 activity
- 1 January 1996
- book chapter
- Published by Elsevier
- Vol. 272, 105-114
- https://doi.org/10.1016/s0076-6879(96)72013-x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotypePharmacogenetics, 1995
- Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.British Journal of Clinical Pharmacology, 1995
- Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in HumansBiochemistry, 1994
- A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratioPharmacogenetics, 1992
- Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsPharmacogenetics, 1992
- Limitation to the use of the urinary S‐/R‐mephenytoin ratio in pharmacogenetic studies.British Journal of Clinical Pharmacology, 1991
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989
- Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiaeBiochemistry, 1989
- A convenient assay for mephenytoin 4-hydroxylase activity of human liver microsomal cytochrome P-450Analytical Biochemistry, 1985